

**IN VITRO–IN VIVO
CORRELATIONS**

ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY

Editorial Board:

NATHAN BACK, *State University of New York at Buffalo*

IRUN R. COHEN, *The Weizmann Institute of Science*

DAVID KRITCHEVSKY, *Wistar Institute*

ABEL LAJTHA, *N. S. Kline Institute for Psychiatric Research*

RODOLFO PAOLETTI, *University of Milan*

Recent Volumes in this Series

Volume 414

ENZYMOLGY AND MOLECULAR BIOLOGY OF CARBONYL METABOLISM 6

Edited by Henry Weiner, Ronald Lindahl, David W. Crabb, and T. Geoffrey Flynn

Volume 415

FOOD PROTEINS AND LIPIDS

Edited by Srinivasan Damodaran

Volume 416

PLATELET-ACTIVATING FACTOR AND RELATED LIPID MEDIATORS 2: Roles in Health and Disease

Edited by Santosh Nigam, Gert Kunkel, and Stephen M. Prescott

Volume 417

DENDRITIC CELLS IN FUNDAMENTAL AND CLINICAL IMMUNOLOGY, Volume 3

Edited by Paola Ricciardi-Castagnoli

Volume 418

STREPTOCOCCI AND THE HOST

Edited by Thea Horaud, Anne Bouvet, Roland Leclercq, Henri de Montclos, and Michel Sicard

Volume 419

ADP-RIBOSYLATION IN ANIMAL TISSUES: Structure, Function, and Biology of Mono (ADP-ribosyl) Transferases and Related Enzymes

Edited by Friedrich Haag and Friedrich Koch-Nolte

Volume 420

ADVANCES IN CIRRHOSIS, HYPERAMMONEMIA, AND HEPATIC ENCEPHALOPATHY

Edited by Vicente Felipo

Volume 421

CELLULAR PEPTIDASES IN IMMUNE FUNCTIONS AND DISEASES

Edited by Siegfried Ansorge and Jürgen Langner

Volume 422

DIETARY FAT AND CANCER: Genetic and Molecular Interactions

Edited under the auspices of the American Institute for Cancer Research

Volume 423

IN VITRO-IN VIVO CORRELATIONS

Edited by David Young, John G. Devane, and Jackie Butler

A Continuation Order Plan is available for this series. A continuation order will bring delivery of each new volume immediately upon publication. Volumes are billed only upon actual shipment. For further information please contact the publisher.

IN VITRO-IN VIVO CORRELATIONS

Edited by

David Young

University of Maryland at Baltimore
Baltimore, Maryland

John G. Devane

Elan Corporation, plc
Athlone, Ireland

and

Jackie Butler

Elan Corporation, plc
Athlone, Ireland

PLENUM PRESS • NEW YORK AND LONDON

Library of Congress Cataloging in Publication Data

In vitro-in vivo correlations / edited by David Young, John G. Devane,
and Jackie Butler.

p. cm. -- (Advances in experimental medicine and biology ; v.
423)

Includes bibliographical references and index.

ISBN-13: 978-1-4684-6038-4 e-ISBN-13: 978-1-4684-6036-0

DOI: 10.1007/978-1-4684-6036-0

1. Drugs--Solubility--Testing. 2. Drugs--Bioavailability--
Testing. I. Young, David, 1952-. II. Devane, John G.
III. Butler, Jackie. IV. Series.

RS189.I438 1997

615'.19--dc21

97-17156

CIP

Proceedings of a workshop on In Vivo-In Vitro Relationships,
held September 4 - 6, 1996, in Baltimore, Maryland

© 1997 Plenum Press, New York

Softcover reprint of the hardcover 1st edition 1997

A Division of Plenum Publishing Corporation

233 Spring Street, New York, N. Y. 10013

<http://www.plenum.com>

10 9 8 7 6 5 4 3 2 1

All rights reserved

No part of this book may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise, without written permission from the Publisher

PREFACE

This book represents the invited presentations and some of the posters presented at the conference entitled “*In Vitro-In Vivo* Relationship (IVIVR) Workshop” held in September, 1996. The workshop was organized by the IVIVR Cooperative Working Group which has drawn together scientists from a number of organizations and institutions, both academic and industrial. In addition to Elan Corporation, which is a drug delivery company specializing in the development of ER (Extended Release) dosage forms, the IVIVR Cooperative Working Group consists of collaborators from the University of Maryland at Baltimore, University College Dublin, Trinity College Dublin, and the University of Nottingham in the UK. The principal collaborators are:

Dr. Jackie Butler, Elan Corporation
Prof. Owen Corrigan, Trinity College Dublin
Dr. Iain Cumming, Elan Corporation
Dr. John Devane, Elan Corporation
Dr. Adrian Dunne, University College Dublin
Dr. Stuart Madden, Elan Corporation
Dr. Colin Melia, University of Nottingham
Mr. Tom O’Hara, Elan Corporation
Dr. Deborah Piscitelli, University of Maryland at Baltimore
Dr. Araz Raoof, Elan Corporation
Mr. Paul Stark, Elan Corporation
Dr. David Young, University of Maryland at Baltimore

The purpose of the workshop was to discuss new concepts and methods in the development of *in vitro-in vivo* relationships for ER products. The original idea went back approximately 15 months prior to the workshop itself. For some time, the principal collaborators had been working together on various aspects of dosage form development. It was obvious that more and more of our time was spent discussing issues and aspects of IVIVR development since it plays such a key role in dosage form development, particularly for ER products. We felt it was important to provide a forum where scientists from industry, academia, and regulatory authorities could come together and discuss how best to develop methods in this complex area.

It is also important to emphasize and appreciate the background and context of the workshop. One can readily identify major milestones and initiatives over the last 10 years that have contributed significantly, either directly or indirectly, to the development of IVIVR methodology. In the last 5 years, the pace of these initiatives has accelerated, very much driven by the FDA. In particular, one can identify the SUPAC IR and ER Work-

shops of the early 90s, resulting in the 1995 issuance of the SUPAC IR guidance, with additional draft guidances prepared during 1996. In the context of IVIVR this has culminated in the issuance of the FDA draft guidance on IVIVC, which was completed just prior to the workshop.

At the point where we set a date for this workshop, we did not anticipate being so timely in relation to the issuance of the draft guidance. However, we believe that the discussions and ideas generated during the workshop provided a better understanding of the guidances and gave valuable feedback to the agency in what was the first public forum since the issuance of the guidance.

As one point of clarification, the Cooperative Working Group, who organized this meeting, talk about IVIVR. Many of the speakers and, indeed, the FDA draft guidance, referred to IVIVC. For the purposes of this workshop, these terms were viewed as interchangeable.

CONTENTS

1. Examples of <i>in Vitro</i> – <i>in Vivo</i> Relationships with a Diverse Range of Quality . . .	1
R. J. Rackley	
2. Dissolution Assay Development for <i>in Vitro</i> – <i>in Vivo</i> Correlations: Theory and Case Studies	17
B. R. Rohrs, J. W. Skoug, and G. W. Halstead	
3. <i>In Vitro</i> Dissolution Profile Comparison and IVIVR: Carbamazepine Case	31
P. Sathe, Y. Tsong, and V. P. Shah	
4. A General Framework for Non-Parametric Subject-Specific and Population Deconvolution Methods for <i>in Vivo</i> – <i>in Vitro</i> Correlation	43
D. Verotta	
5. Convolution-Based Approaches for <i>in Vivo</i> – <i>in Vitro</i> Correlation Modeling	53
W. R. Gillespie	
6. Approaches to IVIVR Modelling and Statistical Analysis	67
A. Dunne, T. O’Hara, and J. Devane	
7. Validation of <i>in Vitro</i> – <i>in Vivo</i> Correlation Models	87
D. Young, J. A. Dowell, D. A. Piscitelli, and J. Devane	
8. Examples of Developing <i>in Vitro</i> – <i>in Vivo</i> Relationships	93
J. Butler	
9. The <i>Biopharmaceutical Drug Classification</i> and Drugs Administered in Extended Release (ER) Formulations	111
O. I. Corrigan	
10. Investigating <i>in Vitro</i> Drug Release Mechanisms Inside Dosage Forms: Monitoring Liquid Ingress in HPMC Hydrophilic Matrices Using Confocal Microscopy	129
C. D. Melia, P. Marshall, P. Stark, S. Cunningham, A. Kinahan, and J. Devane	

11. Determination of Critical Manufacturing and Formulation Variables for a Hydrophilic Matrix Tablet Formulation Using an <i>in Vitro</i> Discriminatory Dissolution Method	137
P. Stark, A. Kinahan, S. Cunningham, J. Butler, T. O'Hara, A. Dunne, J. Connolly, and J. Devane	
12. Artificial Neural Network Based <i>in Vitro</i> – <i>in Vivo</i> Correlations	149
A. S. Hussain	
13. Setting Dissolution Specifications for Modified-Release Dosage Forms	159
D. A. Piscitelli and D. Young	
14. Review of Methodologies for the Comparison of Dissolution Profile Data	167
T. O'Hara, A. Dunne, A. Kinahan, S. Cunningham, P. Stark, and J. Devane	
15. Assessing Whether Controlled Release Products with Differing <i>in Vitro</i> Dissolution Rates Have the Same <i>in Vivo</i> – <i>in Vitro</i> Relationship	173
G. Cao and C. Locke	
16. Comparison of Methodologies for Evaluating Regional Intestinal Permeability	181
A. Raoof, D. Moriarty, D. Brayden, O. I. Corrigan, I. Cumming, J. Butler, and J. Devane	
17. <i>In Vitro</i> – <i>in Vivo</i> Relationships of Several “Immediate” Release Tablets Containing a Low Permeability Drug	191
J. E. Polli	
18. Nonlinear <i>in Vitro</i> – <i>in Vivo</i> Correlations	199
J. Mendell-Harary, J. Dowell, S. Bigora, D. Piscitelli, J. Butler, C. Farrell, J. Devane, and D. Young	
19. Use of Nonlinear Mixed Effects Modelling in the Development of <i>in Vitro</i> – <i>in Vivo</i> Correlations	207
S. Bigora, D. Piscitelli, J. Dowell, J. Butler, C. Farrell, J. Devane, and D. Young	
20. The Development of a Novel <i>in Vitro</i> Discriminatory Dissolution Method for a Class I Drug in a Matrix Tablet Formulation	217
C. Farrell, J. Butler, P. Stark, H. Madden, and J. Devane	
21. <i>In Vivo</i> – <i>in Vitro</i> Evaluation of the Impact of Accelerated Stability Conditions on a Hydrophilic Matrix Tablet	221
P. Stark, A. Kinahan, S. Cunningham, C. Farrell, J. Butler, M. Reilly, and J. Devane	
22. Development of <i>in Vitro</i> – <i>in Vivo</i> Correlations Using Various Artificial Neural Network Configurations	225
J. A. Dowell, A. S. Hussain, P. Stark, J. Devane, and D. Young	
23. Impact of IVIVR on Product Development	241
J. Devane	

24. The Role of <i>in Vitro–in Vivo</i> Correlations (IVIVC) to Regulatory Agencies	261
H. J. Malinowski	
25. Draft Guidance for Industry Extended-Release Solid Oral Dosage Forms: Development, Evaluation and Application of <i>in Vitro–in Vivo</i> Correlations	269
H. Malinowski, P.K. Marroum, V. R. Uppoor, W. Gillespie, H.-Y. Ahn, P. Lockwood, J. Henderson, R. Baweja, M. Hossain, N. Fleischer, L. Tillman, A. Hussain, V. Shah, A. Dorantes, R. Zhu, H. Sun, K. Kumi, S. Machado, V. Tammara, T. E. Ong-Chen, H. Mahayni, L. Lesko, and R. Williams	
26. Issues Important to <i>in Vitro–in Vivo</i> Correlation: IVIVR Workshop Open Discussion	289
Index	297